JP2015508284A5 - - Google Patents

Download PDF

Info

Publication number
JP2015508284A5
JP2015508284A5 JP2014548019A JP2014548019A JP2015508284A5 JP 2015508284 A5 JP2015508284 A5 JP 2015508284A5 JP 2014548019 A JP2014548019 A JP 2014548019A JP 2014548019 A JP2014548019 A JP 2014548019A JP 2015508284 A5 JP2015508284 A5 JP 2015508284A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
nucleic acid
homodimeric protein
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014548019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508284A (ja
JP6258864B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/076404 external-priority patent/WO2013092875A1/en
Publication of JP2015508284A publication Critical patent/JP2015508284A/ja
Publication of JP2015508284A5 publication Critical patent/JP2015508284A5/ja
Application granted granted Critical
Publication of JP6258864B2 publication Critical patent/JP6258864B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014548019A 2011-12-21 2012-12-20 Hpvに対するワクチン Active JP6258864B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578542P 2011-12-21 2011-12-21
US61/578,542 2011-12-21
PCT/EP2012/076404 WO2013092875A1 (en) 2011-12-21 2012-12-20 Vaccines against hpv

Publications (3)

Publication Number Publication Date
JP2015508284A JP2015508284A (ja) 2015-03-19
JP2015508284A5 true JP2015508284A5 (enExample) 2016-02-18
JP6258864B2 JP6258864B2 (ja) 2018-01-10

Family

ID=47471832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548019A Active JP6258864B2 (ja) 2011-12-21 2012-12-20 Hpvに対するワクチン

Country Status (17)

Country Link
US (1) US9901635B2 (enExample)
EP (2) EP2793937B1 (enExample)
JP (1) JP6258864B2 (enExample)
KR (1) KR102057265B1 (enExample)
CN (1) CN104039833B (enExample)
AU (1) AU2012356969B2 (enExample)
BR (1) BR112014015016B1 (enExample)
CA (1) CA2858963C (enExample)
DK (1) DK2793937T3 (enExample)
ES (1) ES2730718T3 (enExample)
HU (1) HUE043361T2 (enExample)
IL (1) IL233217B (enExample)
PT (1) PT2793937T (enExample)
RU (1) RU2644201C2 (enExample)
TR (1) TR201908199T4 (enExample)
WO (1) WO2013092875A1 (enExample)
ZA (1) ZA201404516B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014140176A1 (en) * 2013-03-15 2014-09-18 Vaccibody As Targeting vaccines for veterinary use
US10286058B2 (en) 2014-01-13 2019-05-14 Baylor Research Institute Vaccines against HPV and HPV-related diseases
WO2016024255A1 (en) 2014-08-15 2016-02-18 Genexine, Inc. Methods of treating cervical cancer
AU2016309743B2 (en) * 2015-08-20 2019-02-07 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
CA3008437A1 (en) 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
EP3678699A1 (en) * 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
US12268736B2 (en) 2017-09-07 2025-04-08 University Of Oslo Vaccine molecules
AU2021252155A1 (en) 2020-04-09 2022-12-08 Nykode Therapeutics ASA Individualized therapeutic anticancer vaccine
CN115551547A (zh) 2020-04-24 2022-12-30 格纳西尼有限公司 宫颈癌治疗方法
JP2023524054A (ja) 2020-05-01 2023-06-08 ナイコード セラピューティクス アルメン アクスイェ セルスカプ ベータコロナウイルスの予防と治療
CA3212592A1 (en) 2021-03-26 2022-09-29 Agnete Fredriksen Therapeutic combination for treating cancer
EP4333881A1 (en) 2021-05-03 2024-03-13 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
US20250195632A1 (en) 2021-05-10 2025-06-19 Nykode Therapeutics ASA Tolerance-inducing constructs and composition and their use for the treatment of immune disorders
MX2023013308A (es) 2021-05-10 2024-02-14 Nykode Therapeutics ASA Co-expresion de construcciones y compuestos inmunoinhibidores.
IL308310A (en) 2021-05-10 2024-01-01 Nykode Therapeutics ASA Co-expression of immune-stimulating structures and compounds
WO2022238363A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
US20250288654A1 (en) 2021-05-10 2025-09-18 Nykode Therapeutics ASA Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
EP4426344A1 (en) 2021-11-03 2024-09-11 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
BR0314529A (pt) * 2002-10-03 2005-08-09 Wyeth Corp Polipeptìdeos de papilomavìrus humano e composições imunogênicas
US8932603B2 (en) 2003-02-25 2015-01-13 Vaccibody As Modified antibody
EP1576967B1 (en) * 2004-03-18 2007-09-12 Institut Pasteur Recombinant protein, carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof, therapeutic uses thereof
EP1846026A4 (en) 2005-01-26 2008-07-02 Univ Johns Hopkins ANTIBODY DNA VACCINE WITH PLASMIDES FOR CODING A MUTATED ONCOPROTEIN ANTIGEN AND CALRETICULIN
CN102985109B (zh) * 2010-06-25 2016-05-11 瓦西博迪公司 同型二聚体蛋白质构建体

Similar Documents

Publication Publication Date Title
JP2015508284A5 (enExample)
RU2014129788A (ru) Вакцины против hpv
CN108434450B (zh) 基于铁蛋白纳米颗粒的疫苗及其制备方法
JP2013532971A5 (enExample)
Liu et al. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture
JP2015119730A5 (enExample)
JP2012095652A5 (enExample)
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
RU2013103335A (ru) Конструкции гомодимерных белков
BRPI0416393A (pt) molécula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, métodos para produzir as mesmas, para prevenir infecção por hpv, e para induzir uma resposta imune em um animal, vacina, composições farmacêuticas, e, polipeptìdeo hpv58 l1 isolado e purificado
WO2008098484A1 (en) Recombinant l1 proteins of human papilloma virus and uses thereof
JP2019506175A5 (enExample)
JP2010166921A5 (enExample)
RU2677799C2 (ru) Модифицированные суперспиральные белки с улучшенными свойствами
JP2016533332A5 (enExample)
JP2015501840A5 (enExample)
CN104710515B (zh) 人乳头瘤病毒l1蛋白突变体及其制备方法
CN102747047A (zh) 人乳头瘤病毒型别杂合病毒样颗粒及其制备方法
JP2012515557A5 (enExample)
JP2014519817A5 (enExample)
CN105296521A (zh) 表达可溶性人乳头瘤病毒16亚型l1蛋白的重组质粒及其表达方法
JP2014530224A (ja) ノロウイルス感染に対するワクチンとしての自己集合ペプチドナノパーティクル
Motevalli et al. Supercharged green fluorescent protein delivers HPV16E7 DNA and protein into mammalian cells in vitro and in vivo
JP2013531991A5 (enExample)
JP2019502404A5 (enExample)